Pilot study of blood biomarker candidates for detection of pancreatic cancer

Pancreas

Volumn 39, Issue 7, 2010, Pages 981-988

  Chen, Ru ^a   Crispin, David A ^a   Pan, Sheng ^b   Hawley, Sarah ^c   McIntosh, Martin W ^d   May, Damon ^d   Anton Culver, Hoda ^e   Ziogas, Argyrios ^e   Bronner, Mary P ^f   Brentnall, Teresa A ^a  

^a Department of Medicine   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c Canary Foundation   (United States)

^d Fred Hutchinson Cancer Research Center   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f LERNER RESEARCH INSTITUTE   (United States)

Author keywords

biomarker; early detection; pancreatic cancer; pancreatitis

Indexed keywords

A DISINTEGRIN AND METALLOPROTEINASE DOMAIN 8; CALVASCULIN; CARCINOEMBRYONIC ANTIGEN RELATED CELL ADHESION MOLECULE 5; DISINTEGRIN; GALECTIN 3; LIPOCORTIN 5; MACROPHAGE MIGRATION INHIBITION FACTOR; MATRILYSIN; NEUTROPHIL GELATINASE ASSOCIATED LIPOCALIN; OSTEOPONTIN; SOMATOMEDIN B; SYNDECAN 1; THROMBOSPONDIN 2; TUMOR MARKER; UNCLASSIFIED DRUG;

ARTICLE; CANCER DIAGNOSIS; CANCER STAGING; CONTROLLED STUDY; DISEASE CONTROL; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; MACROPHAGE MIGRATION; OUTCOME ASSESSMENT; PANCREAS CANCER; PANCREATITIS; PILOT STUDY; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; STATISTICAL SIGNIFICANCE;

CA-19-9 ANTIGEN; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; OSTEOPONTIN; PANCREATIC NEOPLASMS; PILOT PROJECTS; ROC CURVE; TUMOR MARKERS, BIOLOGICAL;

EID: 77957366327     PISSN: 08853177     EISSN: None     Source Type: Journal    
DOI: 10.1097/MPA.0b013e3181dac920     Document Type: Article

References (26)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2006. CA Cancer J Clin. 2006;56:106-130.
2. Tsuchiya R, Noda T, Harada N, et al. Collective review of small carcinomas of the pancreas. Ann Surg. 1986;203:77-81.
3. Steinberg W. The clinical utility of the CA 19-9 tumor-associated antigen. Am J Gastroenterol. 1990;85:350-355.
4. Grote T, Logsdon CD. Progress on molecular markers of pancreatic cancer. Curr Opin Gastroenterol. 2007;23:508-514.
5. Misek DE, Patwa TH, Lubman DM, et al. Early detection and biomarkers in pancreatic cancer. J Natl Compr Canc Netw. 2007;5:1034-1041.
6. Chen R, Pan S, Brentnall TA, et al. Proteomic profiling of pancreatic cancer for biomarker discovery. Mol Cell Proteomics. 2005;4:523-533.
7. Chen R, Pan S, Crispin DA, et al. Gene expression and proteomic analysis of pancreatic cancer: a recent update. Cancer Genomics and Proteomics. 2006;3:1-10.
8. Harsha HC, Kandasamy K, Ranganathan P, et al. A compendium of potential biomarkers of pancreatic cancer. PLoS Med. 2009;6:e1000046.
9. Rai AJ, Chan DW. Cancer proteomics: serum diagnostics for tumor marker discovery. Ann N Y Acad Sci. 2004;1022:286-294.
10. Pepe MS, Etzioni R, Feng Z, et al. Phases of biomarker development for early detection of cancer. J Natl Cancer Inst. 2001;93:1054-1061.
11. McIntosh MW, Drescher C, Karlan B, et al. Combining CA 125 and SMR serum markers for diagnosis and early detection of ovarian carcinoma. Gynecol Oncol. 2004;95:9-15.
12. Pepe MS, Longton G. Standardizing diagnostic markers to evaluate and compare their performance. Epidemiology. 2005;16:598-603.
13. Pepe MS. The statistical evaluation of medical tests for classification and prediction. Oxford, UK: Oxford University Press; 2003.
14. Palmer C, Duan X, Hawley S, et al. Systematic evaluation of candidate blood markers for detecting ovarian cancer. PLoS ONE. 2008;3:e2633.
15. Chen R, Pan S, Aebersold R, et al. Proteomics studies of pancreatic cancer. Proteomics Clin Appl. 2007;1:1582-1591.
16. Koopmann J, Fedarko NS, Jain A, et al. Evaluation of osteopontin as biomarker for pancreatic adenocarcinoma. Cancer Epidemiol Biomarkers Prev. 2004;13:487-491.
17. Ozkan H, Kaya M, Cengiz A. Comparison of tumor marker CA 242 with CA 19-9 and carcinoembryonic antigen (CEA) in pancreatic cancer. Hepatogastroenterology. 2003;50:1669-1674.
18. Kuhlmann KF, van Till JW, Boermeester MA, et al. Evaluation of matrix metalloproteinase 7 in plasma and pancreatic juice as a biomarker for pancreatic cancer. Cancer Epidemiol Biomarkers Prev. 2007;16:886-891.
19. Moniaux N, Chakraborty S, Yalniz M, et al. Early diagnosis of pancreatic cancer: neutrophil gelatinase-associated lipocalin as a marker of pancreatic intraepithelial neoplasia. Br J Cancer. 2008;98: 1540-1547.
20. Chen R, Brentnall TA, Pan S, et al. Quantitative proteomics analysis reveals that proteins differentially expressed in chronic pancreatitis are also frequently involved in pancreatic cancer. Mol Cell Proteomics. 2007;6:1331-1342.
21. Kolb A, Kleeff J, Guweidhi A, et al. Osteopontin influences the invasiveness of pancreatic cancer cells and is increased in neoplastic and inflammatory conditions. Cancer Biol Ther. 2005;4:740-746.
22. Friess H, Ding J, Kleeff J, et al. Microarray-based identification of differentially expressed growth- and metastasis-associated genes in pancreatic cancer. Cell Mol Life Sci. 2003;60:1180-1199.
23. Juuti A, Nordling S, Lundin J, et al. Syndecan-1 expression - a novel prognostic marker in pancreatic cancer. Oncology. 2005;68: 97-106.
24. Pan S, Aebersold R, Chen R, et al. Mass spectrometry based targeted protein quantification: methods and applications. J Proteome Res. 2009;8:787-797.
25. Goonetilleke KS, Siriwardena AK. Systematic review of carbohydrate antigen (CA 19-9) as a biochemical marker in the diagnosis of pancreatic cancer. Eur J Surg Oncol. 2007;33:266-270.
26. Sandblom G, Granroth S, Rasmussen IC. TPS, CA 19-9, VEGF-A, and CEA as diagnostic and prognostic factors in patients with mass lesions in the pancreatic head. Ups J Med Sci. 2008;113:57-64.